Friday, 16 October 2026European Markets

OCI Stock Impressive Rise On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with OCI (OCI.AS) rising 11.92% to €22.20 on Thursday while AEX-Index rose 0.37% to €789.91.

OCI's last close was €19.83, 47.01% under its 52-week high of €37.42.

About OCI

OCI N.V. produces and distributes hydrogen-based and natural gas-based products to agricultural, transportation, and industrial customers. It operates through Methanol US, Methanol Europe, Nitrogen US, Nitrogen Europe, and Fertiglobe segments. The company offers anhydrous ammonia, granular urea, urea ammonium nitrate solution, calcium ammonium nitrate, ammonium sulphate, aqueous ammonia, nitric acid, urea solution, bio-methanol, methanol, melamine, and diesel exhaust fluid, as well as other nitrogen products. It also owns and operates an ammonia terminal at the port of Rotterdam. The company has operations in Europe, the Americas, the Middle East, Africa, Asia, and Oceania. OCI N.V. has a strategic partnership with Abu Dhabi National Oil Company. OCI N.V. was founded in 2013 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, OCI has a trailing twelve months EPS of €-1.08.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.32%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

OCI's EBITDA is 1.05.

Revenue Growth

Year-on-year quarterly revenue growth declined by 54.1%, now sitting on 6.01B for the twelve trailing months.

Sales Growth

OCI's sales growth is negative 27.2% for the current quarter and 85.2% for the next.

Moving Average

OCI's value is below its 50-day moving average of €22.24 and below its 200-day moving average of €24.32.

More news about OCI (OCI.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com